Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Adult
Aged
Aged, 80 and over
Antigens, CD
/ genetics
Antigens, Differentiation, Myelomonocytic
/ genetics
B7-H1 Antigen
/ genetics
CD4-Positive T-Lymphocytes
/ immunology
Central Nervous System Diseases
/ epidemiology
Disease-Free Survival
Female
Humans
India
/ epidemiology
Lymphocytes, Tumor-Infiltrating
/ immunology
Lymphoma, Large B-Cell, Diffuse
/ epidemiology
Male
Middle Aged
Prognosis
Programmed Cell Death 1 Receptor
/ genetics
Receptors, Cell Surface
/ genetics
Tumor Microenvironment
Central nervous system
PD-L1
diffuse large B-cell lymphoma
tumor microenvironment
tumor-infiltrating lymphocytes
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
16
06
2021
accepted:
28
11
2021
pubmed:
5
12
2021
medline:
1
2
2022
entrez:
4
12
2021
Statut:
ppublish
Résumé
Primary central nervous system-diffuse large B-cell lymphoma (PCNS-DLBCL) is a rare, extranodal malignant lymphoma carrying poor prognosis. The prognostic impact of tumor microenvironment (TME) composition and the PD-1/PD-L1 immune checkpoint pathway are still undetermined in PCNS-DLBCL. We aimed to quantify the tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs), and PD-L1 expression in the PCNSL and evaluated their prognostic significance. All patients with histopathologically diagnosed PCNS-DLBCL over a period of 7 years were recruited. Immunohistochemistry for CD3, CD4, CD8, FOXP3, CD68, CD163, PD-1, and PD-L1 was performed on the tissue microarray. Forty-four cases of PCNS-DLBCL, who satisfied the selection criteria, were included with mean age of 55 ± 12.3 years and male-to-female ratio of 0.91:1. The mean overall survival (OS) and disease-free survival (DFS) was 531.6 days and 409.8 days, respectively. Among TILs, an increased number of CD3+ T cells showed better OS and DFS, without achieving statistical significance. CD4 positive T-cells were significantly associated with the longer OS (p = 0.037) and DFS (p = 0.023). TAMs (68CD and CD163 positive) showed an inverse relationship with OS and DFS but did not reach statistical significance (p > 0.05). Increased PD-L1 expression in immune cells, but not in tumor cells, was associated with significantly better DFS (p = 0.037). The TME plays a significant role in the prognosis of PCNS-DLBCL. Increased number of CD4+ T cells and PD-L1-expressing immune cells is associated with better prognosis in PCNS-DLBCL. Further studies with larger sample size are required to evaluate the role of targeted therapy against the TME and immune check point inhibitors in this disease.
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
B7-H1 Antigen
0
CD163 antigen
0
CD274 protein, human
0
Programmed Cell Death 1 Receptor
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-94Informations de copyright
© 2021 Scandinavian Societies for Medical Microbiology and Pathology.
Références
Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16(7):e322-32.
Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol. 2013;9(6):317-27.
Hattab EM, Martin SE, Al-Khatib SM, Kupsky WJ, Vance GH, Stohler RA, et al. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol. 2010;23(2):235-43.
Radotra BD, Parkhi M, Chatterjee D, Yadav BS, Ballari NR, Prakash G, et al. Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: experience from a Tertiary Center in North India. Surg Neurol Int. 2020;11:424.
Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14(8):517-34.
Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016;101(5):531-40.
Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-8.
Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop. 2011;51(2):93-9.
Cho H, Kim SH, Kim S-J, Chang JH, Yang WI, Suh C-O, et al. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma. Ann Hematol. 2017;96(7):1163-73.
Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203-20.
Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869-81.
Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071-3.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-82.
Ponzoni M, Berger F, Chassagne-Clement C, Tinguely M, Jouvet A, Ferreri AJM, et al. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol. 2007;138(3):316-23.
He M, Zuo C, Wang J, Liu J, Jiao B, Zheng J, et al. Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma. Neuro Oncol. 2013;15(6):727-34.
Kumari N, Krishnani N, Rawat A, Agarwal V, Lal P. Primary central nervous system lymphoma: prognostication as per international extranodal lymphoma study group score and reactive CD3 collar. J Postgrad Med. 2009;55(4):247-51.
Alame M, Pirel M, Costes-Martineau V, Bauchet L, Fabbro M, Tourneret A, et al. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas. Virchows Arch. 2020;476(6):891-902.
Pardoll DM, Topalian SL. The role of CD4+ Tcell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-94.
Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol. 2013;88(4):273-6.
Xu Y, Kroft SH, McKenna RW, Aquino DB. Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study. Br J Haematol. 2001;112(4):945-9.
Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001;19(3):720-6.
Marcelis L, Antoranz A, Delsupehe A-M, Biesemans P, Ferreiro JF, Debackere K, et al. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother. 2020;69(9):1751-66.
Nam SJ, Kim S, Kwon D, Kim H, Kim S, Lee E, et al. Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology. 2018;7(7):e1442164.
Sasayama T, Tanaka K, Mizowaki T, Nagashima H, Nakamizo S, Tanaka H, et al. Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in primary central nervous system lymphoma (PCNSL). Brain Pathol. 2016;26(4):479-87.
Four M, Cacheux V, Tempier A, Platero D, Fabbro M, Marin G, et al. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol. 2017;35(4):487-96.
Cho H, Kim SH, Kim S-J, Chang JH, Yang W-I, Suh C-O, et al. Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. Oncotarget. 2017;8(50):87317-28.
Abdulla M, Alexsson A, Sundström C, Ladenvall C, Mansouri L, Lindskog C, et al. PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. Acta Oncol. 2021;60(4):531-8.
Hayano A, Komohara Y, Takashima Y, Takeya H, Homma J, Fukai J, et al. Programmed cell death ligand 1 expression in primary central nervous system lymphomas: a clinicopathological study. Anticancer Res. 2017;37(10):5655-66.
Furuse M, Kuwabara H, Ikeda N, Hattori Y, Ichikawa T, Kagawa N, et al. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer. 2020;20(1):277.
Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208-22.
Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, et al. PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302-11.
Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24(6):392-7.
Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, et al. Food and drug administration approval summary: atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res. 2017;23(16):4534-9.
Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol. 2018;26(2):83-3.
Huang TH, Cheng W, Wang YH. Interpretation according to clone-specific PD-L1 cutoffs reveals better concordance in muscle-invasive urothelial carcinoma. Diagnostics. 2021;11(3):448.